Clinical Trial Update: Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study results for INCB001158, an arginase inhibitor, as a single agent and in combination with immune checkpoint therapy, in patients with advanced/meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Lung Cancer
• Mesothelioma
• Renal Cell Carcinoma
• Urothelial Cancer

Drugs mentioned

• INCB001158

Snippet

Sponsor: Incyte Corporation | Conditions: Metastatic Cancer, Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2021-09-30